IRVINE, Calif. – January 21, 2019 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the company will be presenting at two upcoming healthcare conferences. AIVITA’s Chief Medical Officer Dr. Robert O. Dillman will be presenting at Precision Medicine World Conference on Tuesday, Jan. 22, in Santa Clara, California. AIVITA Chairman and Chief Executive Officer Dr. Hans S. Keirstead will speak at Phacilitate Leaders World on Wednesday, Jan. 23, in Miami, Florida.

Precision Medicine World Conference in Silicon Valley is a healthcare conference for that provides attendees with an opportunity to learn about the latest developments and advancements in precision medicine. Dr. Dillman will be presenting details on AIVITA’s autologous cancer vaccine technology on Tuesday, Jan. 22, at 2:45 p.m. in a talk titled Patient-Specific Cancer Vaccines. He will share past and current clinical data in a presentation focused on antigens from autologous tumor initiating cells.

Co-located with the World Stem Cell Summit, Phacilitate Leaders World is an advanced therapies partnering event that provides attendees with a platform to build new partnerships and discuss cutting-edge therapies. On Wednesday, Jan. 23, at 2:35 p.m. Dr. Keirstead will deliver a talk titled Targeting the Cancer Stem Cell: Clinical Data and Mechanism of Action.

About ROOT OF CANCER

AIVITA’s treatment is a platform technology applicable to most solid tumor types and consists of autologous dendritic cells loaded with autologous tumor antigens from autologous self-renewing tumor-initiating cells.

AIVITA’s ovarian Phase 2 double-blind study is active and enrolling approximately 99 patients who will be randomized in a 2:1 ratio to receive either the autologous dendritic cell vaccine or autologous monocytes as a comparator.

Patients eligible for randomization and treatment will be those (1) who have undergone debulking surgery, (2) for whom a cell line has been established, (3) who have undergone leukapheresis from which sufficient monocytes were obtained, (4) have an ECOG performance grade of 0 or 1 (Karnofsky score of 70-100%), and (5) who have completed primary therapy.

For additional information about AIVITA’s AVOVA-1 trial patients can visit: www.clinicaltrials.gov/ct2/show/NCT02033616

AIVITA’s glioblastoma Phase 2 single-arm study is active and will enroll approximately 55 patients to receive the treatment candidate.

Patients eligible for treatment will be those (1) who have recovered from surgery such that they are about to begin concurrent chemotherapy and radiation therapy (CT/RT), (2) for whom an autologous tumor cell line has been established, (3) have a Karnofsky Performance Status of > 70 and (4) have undergone successful leukapheresis from which peripheral blood mononuclear cells (PBMC) were obtained that can be used to generate dendritic cells (DC).

For additional information about AIVITA’s AV-GBM-1 trial please visit: www.clinicaltrials.gov/ct2/show/NCT03400917

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA’s skin care products support the treatment of women with ovarian cancer.

###